logo-loader
viewHumanigen, Inc.

Humanigen teams up with Kite to treat a type of lymphoma cancer

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based biotech has forged a clinical collaboration with Gilead Sciences Inc's (NASDAQ:GILD) subsidiary Kite, to study its therapy lenzilumab, with Kite's drug called Yescarta in patients suffering with certain forms of lymphoma cancer.

Durrant says he expects this Phase 1/2 study to begin by the end of 2019.

Quick facts: Humanigen, Inc.

Price: 0.3641 USD

OTCQB:HGEN
Market: OTCQB
Market Cap: $41.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen updates on its clinical collaboration with Gilead Sciences...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant spoke with Proactive at the 2019 BIO Investor Forum in San Francisco.  Durrant updated investors on the opportunity within its clinical collaboration with Kite, a company belonging to Gilead Sciences Inc (NASDAQ:GILD), along with...

on 10/23/2019

2 min read